|
Hematology/Oncology Research Studies: Open for Enrollment | Date: 05/17/19 |
|---|
| NCT#/Phase: | NCT01842672 Phase 1/2a |
|---|---|
| IRB#: | 2017-037 |
| Description: | This study will evalute the maximum tolerated dose and response rate of the combination of mitoxantrone and clofarabine as reinduction therapy for patients with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL). |
| Inclusion: | Individuals who are <= 30 years of age with relapsed or refractory acute leukemia or NHL. |
| Enrollment Status: | Open for enrollment |
| Sponsor: | New York Medical College |
| Principal Investigator(s): | Jennifer Michlitsch, MD |
| Contact(s): | Anu Agrawal, MD (510-428-3885 x3539) Jennifer Michlitsch, MD |
| Study Link: | https://clinicaltrials.gov/ct2/show/NCT01842672 |